HHS and FDA announced draft guidance establishing a "plausible mechanism" pathway to speed approval of individualized therapies for rare and ultra‑rare genetic diseases, highlighted by the case of baby “KJ.” Officials described how the framework would let well‑controlled investigations and real‑world evidence support approvals, and scientists, families, and reporters discussed implementation and oversight.